Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clarient, a provider of anatomic pathology and molecular testing services, has announced the commercial launch of its new gene expression test for prostate cancer.
Subscribe to our email newsletter
This new test will be available through Clarient’s PATHSiTE virtual reporting tool and accessible to the company’s entire pathology network.
Clarient said that the new test is based on a unique and patent-protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher prostate cancer cells in prostate tissue. The association of these four genes with prostate cancer was discovered by Health Discovery using its patented SVM and SVM-RFE pattern recognition technology.
The two companies also announced that in order to insure market uptake of the new prostate cancer test, they will transition to a non-exclusive agreement to allow for licensing to additional laboratories. Under the amended agreement, Clarient will retain the exclusive rights for a prognostic test which may be developed in the future in conjunction with Health Discovery.